39 — Iatrogenic Psychiatry: When Treatment Produces New Symptoms
Series: Treatment Resistance Reconsidered
Evidence class: Established drug adverse-effect syndromes

Abstract
A patient may become more agitated, sleepless, emotionally blunted or cognitively slowed during treatment for a psychiatric disorder. Such changes can result from illness progression, environmental factors or the treatment itself. Distinguishing them requires a temporal medication history and careful examination. Akathisia, medication-induced activation, sedation, withdrawal phenomena and other adverse effects demonstrate that not every symptom arising during therapy represents the untreated disease.

The akathisia example
Akathisia involves an often intensely distressing internal restlessness with observable movement or difficulty remaining still. It is associated with antipsychotic medications and has also been reported with other psychotropic classes. A patient may describe panic, agitation or unbearable internal discomfort rather than use the term akathisia. Increasing medication under the assumption that agitation represents worsening psychosis could worsen an adverse drug effect in some situations. Standardized evaluation and recognition of timing are important.

Activation, sedation and withdrawal
Medication changes can alter sleep, autonomic state and cognitive performance. Activation after initiation or dose escalation requires distinction from mania, anxiety and ordinary treatment adjustment. Sedation can be mistaken for depressive slowing; emotional blunting for persistent anhedonia. Abrupt withdrawal of some medications can produce distressing physiological and psychiatric symptoms. The relationship between onset and prescription changes is informative but not sufficient by itself: worsening illness can happen at the same time.

A chronology-centered method
A useful medication timeline records agent, dose, start, titration, discontinuation, concurrent drugs and the first appearance of each symptom. The clinician asks whether symptoms were present before exposure, whether they are recognized adverse-effect patterns and whether an alternative medical explanation is plausible. A clinically supervised medication adjustment may clarify cause, but unsafe abrupt discontinuation or unmonitored changes are not appropriate experiments.

Why the idea matters for medical theory
The phrase “treatment resistance” can conceal an adverse-effect phenotype, while the phrase “drug toxicity” can conceal illness progression. Both are forms of premature causal closure. A serious systems model examines interventions as new biological exposures with intended and unintended effects, and accepts that the safest action may sometimes be simplification rather than intensification.

Conclusion
Iatrogenic neuropsychiatric symptoms are real and clinically significant. Accurate attribution requires temporal detail, recognized syndromes and medical judgment; it does not support dismissing psychiatric medications in general, many of which provide substantial benefit.

Selected readings
- Pringsheim et al., The Assessment and Treatment of Antipsychotic-Induced Akathisia: https://pmc.ncbi.nlm.nih.gov/articles/PMC6299189/
- Bousman et al., Antidepressant metabolism and tolerability: https://pmc.ncbi.nlm.nih.gov/articles/PMC10564324/